Kyverna Therapeutics (NASDAQ:KYTX) Posts Earnings Results, Beats Expectations By $0.04 EPS

Kyverna Therapeutics (NASDAQ:KYTX) released its quarterly earnings results on Tuesday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.04, FiscalAI reports.

Kyverna Therapeutics Trading Up 1.6%

KYTX stock traded up $0.13 during midday trading on Tuesday, reaching $8.02. The stock had a trading volume of 657,572 shares, compared to its average volume of 934,387. The business has a fifty day simple moving average of $8.05 and a two-hundred day simple moving average of $8.48. The company has a quick ratio of 8.15, a current ratio of 8.15 and a debt-to-equity ratio of 0.13. The firm has a market cap of $487.54 million, a price-to-earnings ratio of -2.45 and a beta of 1.93. Kyverna Therapeutics has a twelve month low of $2.80 and a twelve month high of $13.67.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Empowered Funds LLC acquired a new stake in shares of Kyverna Therapeutics during the 4th quarter worth approximately $169,000. AQR Capital Management LLC acquired a new position in Kyverna Therapeutics in the first quarter valued at approximately $137,000. Federated Hermes Inc. lifted its holdings in Kyverna Therapeutics by 22.2% in the second quarter. Federated Hermes Inc. now owns 44,000 shares of the company’s stock valued at $135,000 after buying an additional 8,000 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Kyverna Therapeutics by 31.1% in the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after acquiring an additional 16,267 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Kyverna Therapeutics in the second quarter valued at approximately $107,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. JPMorgan Chase & Co. lowered their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kyverna Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $30.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.